TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04660773
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral medication
Study: NCT04636671
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per-protocol methylprednisolone administration and tapering (see arm description)
Study: NCT04636671
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per-protocol dexamethasone administration (see arm description)
Study: NCT05331105
Drug: HL-085
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen.
Study: NCT05964920
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two placebo injections one at baseline and one week 3.
Study: NCT05964920
Drug: Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
Study: NCT06651281
Drug: Tulisokibart
Normalized name: Tulisokibart
DrugBank: Tulisokibart (DB18719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
Study: NCT06292351
Drug: DMB-I (Dimebon)
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
Study: NCT06345599
Drug: Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
Study: NCT06174961
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15,000 units of unfractionated heparin administered in the thigh
Study: NCT04463368
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 courses of ipilimumab 3mg/kg every third week
Study: NCT04463368
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 courses of nivolumab 1mg/kg every third week
Study: NCT06413368
Drug: Maralixibat 9.5 MG/ML [Livmarli]
Normalized name: maralixibat 9.5 MG/ML [Livmarli]
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.
Study: NCT05560009
Drug: Fluorodopa F 18
Normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04581408
Drug: Lumacaftor / Ivacaftor, Orkambi® Oral Tablet
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days
Study: NCT06001853
Drug: BM-MSC injection
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
Study: NCT05682599
Drug: Azvudine
Normalized name: Azvudine
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azvudine is a novel nucleoside reverse transcriptase inhibitor.
Study: NCT06041152
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 macrodoses of 25mg separated by one week.
Study: NCT05411991
Drug: Intravenous acetazolamide 500 mg OD
Normalized name: acetazolamide 500 MG
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (\>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.
Study: NCT05411991
Drug: Intravenous canrenoate 200 mg OD
Normalized name: canrenoate
DrugBank: Canrenoic acid (DB09015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L or if serum potassium levels are \>5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
Study: NCT05411991
Drug: Oral potassium supplements
Normalized name: potassium Oral Tablet
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If serum potassium levels are \<3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels \>4 mmol/L
Study: NCT04761614
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IVPB
Study: NCT04761614
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04687540
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
Study: NCT05307003
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication used to treat ICU delirium
Study: NCT05307003
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication used to treat ICU delirium
Study: NCT05327595
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05327595
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT05345678
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 1500mg Route: IV
Study: NCT05345678
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 300mg Route: IV
Study: NCT04604067
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days
Study: NCT05176639
Drug: Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED)
DrugBank: Veligrotug (DB18976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IV Infusions of multiple ascending doses of veligrotug (VRDN-001), ranging from 3 mg/kg to 20 mg/kg
Study: NCT04763616
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
Study: NCT04763616
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
Study: NCT06439693
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-microtubule agent, via intravenous (into the vein) infusion per institutional guidelines.
Study: NCT06439693
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-microtubule agent, via intravenous infusion per institutional guidelines.
Study: NCT06439693
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-microtubule agent, via intravenous infusion per institutional guidelines.
Study: NCT06439693
Drug: Phesgo
Normalized name: Phesgo
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via subcutaneous (under the skin) injection per protocol.
Study: NCT06439693
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous infusion per institutional guidelines.
Study: NCT06439693
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion per institutional guidelines.
Study: NCT06439693
Drug: Trastuzumab Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per institutional guidelines.
Study: NCT06439693
Drug: Trastuzumab Subcutaneous Subcutaneous
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per institutional guidelines.
Study: NCT06439693
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional guidelines.
Study: NCT06439693
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous infusion per institutional guidelines.
Study: NCT00000267
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05137002
Drug: CIN-107
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIN-107 tablets by mouth once daily
Study: NCT04843540
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Rifampin as oral capsule
Study: NCT04711343
Drug: Cosentyx (US-licensed)
Normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
Study: NCT04711343
Drug: Cosentyx (EU-licensed)
Normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
Study: NCT04886297
Drug: Mega Resveratrol® capsules
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
Study: NCT04886297
Drug: Mega Resveratrol® Placebo capsules
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega Resveratrol® Placebo capsules
Study: NCT04656301
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
Study: NCT05645302
Drug: Lidocaine Cataplasms
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
Study: NCT06267820
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: analgesia
Study: NCT05576961
Drug: High dose RX-af01
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
Study: NCT05689853
Drug: AK119
Normalized name: AK119
DrugBank: AK119 (DB16423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK119 is an anti-CD73 monoclonal antibody.
Study: NCT05689853
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
Study: NCT05519085
Drug: mezigdomide
Normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05519085
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05519085
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05519085
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06285799
Drug: Low Dose IHAT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)
Study: NCT06285799
Drug: High Dose IHAT
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)
Study: NCT06285799
Drug: Carob Flour
DrugBank: Carob (DB10852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of 1 placebo capsule (carob flour)
Study: NCT05968690
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol will be administered to patients in all cohorts.
Study: NCT05968690
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone will be administered to patients in cohorts 2, 3, and 4.
Study: NCT03613792
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Benzodiazepine
Study: NCT03613792
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic
Study: NCT00076401
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05627947
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
Study: NCT05098366
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1mg/kg (max 5mg) of IV furosemide
Study: NCT05165550
Drug: Elsulfavirine
Normalized name: Elsulfavirine
DrugBank: Elsulfavirine (DB14929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elsulfavirine (Elpida®) 20 mg capsules for oral administration
Study: NCT06117917
Drug: S-ketamine and pregabalin
Normalized name: (S)-(-)-ketamine
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Study: NCT06117917
Drug: Normal saline and placebo capsule
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours
Study: NCT05251636
Drug: Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard of Care intravitreal aflibercept injection
Study: NCT05833399
Drug: Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
Study: NCT00939614
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05235100
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
Study: NCT05762640
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT.
Study: NCT06285071
Drug: Concizumab
Normalized name: concizumab
DrugBank: Concizumab (DB12820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
Study: NCT05812430
Drug: anlotinib+TQB2450+nab-paclitaxel+cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles.
Study: NCT04813107
Drug: APL-1202 in combination with tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
Study: NCT04813107
Drug: Tislelizumab alone
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
Study: NCT05680142
Drug: superficial cervical plexus block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
Study: NCT05680142
Drug: cervical erector spinae plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
Study: NCT05435560
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
Study: NCT05435560
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
Study: NCT04040465
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
Study: NCT04075136
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection 0.5 MG Per 0.05 ML Injection.